JP6891183B2 - ラパフシン・ライブラリの合成と組成物 - Google Patents

ラパフシン・ライブラリの合成と組成物 Download PDF

Info

Publication number
JP6891183B2
JP6891183B2 JP2018540102A JP2018540102A JP6891183B2 JP 6891183 B2 JP6891183 B2 JP 6891183B2 JP 2018540102 A JP2018540102 A JP 2018540102A JP 2018540102 A JP2018540102 A JP 2018540102A JP 6891183 B2 JP6891183 B2 JP 6891183B2
Authority
JP
Japan
Prior art keywords
rapafcin
library
synthesis
composition
viii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018540102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510738A5 (enExample
JP2019510738A (ja
Inventor
リュー ジュン
リュー ジュン
ワン ジンシン
ワン ジンシン
グオ ズフェン
グオ ズフェン
ホン サム
ホン サム
リュー ウクン
リュー ウクン
ペン ハンジン
ペン ハンジン
ダス マニーシャ
ダス マニーシャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2019510738A publication Critical patent/JP2019510738A/ja
Publication of JP2019510738A5 publication Critical patent/JP2019510738A5/ja
Priority to JP2021088242A priority Critical patent/JP7158532B2/ja
Application granted granted Critical
Publication of JP6891183B2 publication Critical patent/JP6891183B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018540102A 2016-02-04 2017-02-03 ラパフシン・ライブラリの合成と組成物 Active JP6891183B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021088242A JP7158532B2 (ja) 2016-02-04 2021-05-26 ラパフシン・ライブラリの合成と組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662291437P 2016-02-04 2016-02-04
US62/291,437 2016-02-04
PCT/US2017/016481 WO2017136708A1 (en) 2016-02-04 2017-02-03 Synthesis and composition of rapafucin libraries

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021088242A Division JP7158532B2 (ja) 2016-02-04 2021-05-26 ラパフシン・ライブラリの合成と組成物

Publications (3)

Publication Number Publication Date
JP2019510738A JP2019510738A (ja) 2019-04-18
JP2019510738A5 JP2019510738A5 (enExample) 2020-02-06
JP6891183B2 true JP6891183B2 (ja) 2021-06-18

Family

ID=59501078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018540102A Active JP6891183B2 (ja) 2016-02-04 2017-02-03 ラパフシン・ライブラリの合成と組成物
JP2021088242A Active JP7158532B2 (ja) 2016-02-04 2021-05-26 ラパフシン・ライブラリの合成と組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021088242A Active JP7158532B2 (ja) 2016-02-04 2021-05-26 ラパフシン・ライブラリの合成と組成物

Country Status (8)

Country Link
US (1) US10662220B2 (enExample)
EP (1) EP3411413A4 (enExample)
JP (2) JP6891183B2 (enExample)
CN (1) CN108713028B (enExample)
AU (1) AU2017214550B2 (enExample)
CA (1) CA3013589A1 (enExample)
MX (1) MX2018009405A (enExample)
WO (1) WO2017136708A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021138726A (ja) * 2016-02-04 2021-09-16 ザ・ジョンズ・ホプキンス・ユニバーシティ ラパフシン・ライブラリの合成と組成物
US11555054B2 (en) 2016-02-04 2023-01-17 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11708391B2 (en) 2016-02-04 2023-07-25 The Johns Hopkins University Rapaglutins, novel inhibitors of GLUT and use thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2813512B1 (en) 2011-12-28 2021-03-31 Chugai Seiyaku Kabushiki Kaisha Peptide-compound cyclization method
DK3269809T3 (da) 2015-03-13 2022-09-12 Chugai Pharmaceutical Co Ltd MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
US12391971B2 (en) 2017-01-31 2025-08-19 Chugai Seiyaku Kabushiki Kaisha Method for synthesizing peptides in cell-free translation system
JP7232758B2 (ja) * 2017-06-09 2023-03-06 中外製薬株式会社 膜透過性の高い環状ペプチド化合物、及びこれを含むライブラリ
TW202126323A (zh) 2019-10-01 2021-07-16 約翰斯赫普金斯大學 雷帕弗辛（Ｒａｐａｆｕｃｉｎ）衍生化合物及其使用方法
US20220372014A1 (en) * 2019-10-01 2022-11-24 The Johns Hopkins University Neuroprotective compounds and methods of use thereof
CN120271673A (zh) * 2024-01-08 2025-07-08 重庆医科大学 一种化合物、包含其的药物组合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US7056935B2 (en) 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
CN1187127A (zh) * 1995-06-07 1998-07-08 吉尔福特药品有限公司 旋转异构酶活性抑制剂
US6984635B1 (en) 1998-02-13 2006-01-10 Board Of Trustees Of The Leland Stanford Jr. University Dimerizing agents, their production and use
AU766513B2 (en) * 1998-02-13 2003-10-16 Board Of Trustees Of The Leland Stanford Junior University Novel dimerizing agents, their production and use
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US20080306098A1 (en) * 2006-11-06 2008-12-11 Mutz Mitchell W Pharmacokinetics of protease inhibitors and other drugs
WO2010004304A1 (en) * 2008-06-17 2010-01-14 Biotica Technology Limited Novel compounds and methods for their production
AU2011336727B2 (en) * 2010-11-30 2016-11-03 The Johns Hopkins University Hybrid cyclic libraries and screens thereof
EP2607352A1 (en) * 2011-12-22 2013-06-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
EP3007696B1 (en) * 2013-06-14 2019-10-16 The Board of Regents of The University of Texas System Novel allosteric inhibitors of proteasome and methods of use thereof
CN108713028B (zh) 2016-02-04 2021-12-28 约翰霍普金斯大学 rapafucin文库的合成和组合物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021138726A (ja) * 2016-02-04 2021-09-16 ザ・ジョンズ・ホプキンス・ユニバーシティ ラパフシン・ライブラリの合成と組成物
JP7158532B2 (ja) 2016-02-04 2022-10-21 ザ・ジョンズ・ホプキンス・ユニバーシティ ラパフシン・ライブラリの合成と組成物
US11555054B2 (en) 2016-02-04 2023-01-17 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11708391B2 (en) 2016-02-04 2023-07-25 The Johns Hopkins University Rapaglutins, novel inhibitors of GLUT and use thereof

Also Published As

Publication number Publication date
AU2017214550A1 (en) 2018-08-16
US10662220B2 (en) 2020-05-26
CN108713028B (zh) 2021-12-28
JP7158532B2 (ja) 2022-10-21
JP2019510738A (ja) 2019-04-18
WO2017136708A1 (en) 2017-08-10
MX2018009405A (es) 2018-11-09
US20190092808A1 (en) 2019-03-28
EP3411413A1 (en) 2018-12-12
CA3013589A1 (en) 2017-08-10
EP3411413A4 (en) 2019-09-18
JP2021138726A (ja) 2021-09-16
CN108713028A (zh) 2018-10-26
AU2017214550B2 (en) 2024-03-07

Similar Documents

Publication Publication Date Title
JP6891183B2 (ja) ラパフシン・ライブラリの合成と組成物
Milroy et al. Modulators of protein–protein interactions
AU2016255749B2 (en) Compositions and methods for assessing toxicity using Dynamic BH3 profiling
AU2016235424A1 (en) Peptidomimetic macrocycles and uses thereof
Beeston et al. Validation of ion mobility spectrometry‐mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase
KR20100074743A (ko) 초고속 스크리닝용 단백질칩 시스템을 이용한 항체모방 펩타이드 탐색방법
WO2005110456A2 (en) T-cell death-inducing epitopes
Hymel et al. Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain–binding peptide macrocycles
Salcius et al. Identification and characterization of ternary complexes consisting of FKBP12, MAPRE1 and macrocyclic molecular glues
Atkinson et al. Development of small cyclic peptides targeting the CK2α/β interface
Bailey et al. Engineering CRBN for rapid identification of next generation binders
Belcher Chemoproteomic Strategies for Drug Discovery and Natural Product Target Identification
Soini Identification of molecular glues of 14-3-3 Protein-Protein Interactions
Knott Development of Mass Spectrometry-Based Proteomic Approaches for the Study of Diseased Tissues
Melder Development of a Compound Interaction Screen on a photoactivatable Cellulose Membrane (CISCM) to identify drug targets
Ongkingco et al. Reengineering of a Proteomimetic Pan‐Ras Inhibitor into a Ras Degrader
EP4638467A1 (en) Cyclosporine-acridinium esters and methods of production and use thereof
CN118515657A (zh) 一种广谱型细菌选择性核酸探针及其应用
JPWO2005036173A1 (ja) 非特異的物質の除去方法
HK1252055B (en) Compositions and methods for assessing toxicity using dynamic bh3 profiling
KR20190024446A (ko) 고친화성 단백질 포획제, 그것의 스크리닝 방법 및 이를 이용한 단백질 검출 방법
HK1252058B (en) High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210526

R150 Certificate of patent or registration of utility model

Ref document number: 6891183

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250